On January 19, 2023, the U.S. Food and Drug Administration granted accelerated approval to Tucatinib plus Trastuzumab for adult patients with RAS wild-type metastatic colon cancer with HER2-positive status as detected at
For more information contact: Tara Shah (425) 557-5953 [email protected] April 1, 2022, Janakpurdham, Nepal – The Binaytara Foundation Cancer Center (BTFCC) is pleased to welcome Dr. Rubina Suwal, who will perform head
More